A First Appraisal of Cryptographic Mechanisms for the Selective Disclosure of Verifiable Credentials

被引:2
|
作者
Flamini, Andrea [2 ]
Ranise, Silvio [1 ,2 ]
Sciarretta, Giada [1 ]
Scuro, Mario [2 ]
Sharif, Amir [1 ]
Tomasi, Alessandro [1 ]
机构
[1] FBK, Ctr Cybersecur, Trento, Italy
[2] Univ Trento, Dept Math, Trento, Italy
关键词
Selective Disclosure; Verifiable Credentials; Zero-Knowledge Proof; eIDAS; 2; GDPR;
D O I
10.5220/0012084000003555
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Verifiable credentials are a digital analogue of physical credentials. Their authenticity and integrity are protected by means of cryptographic techniques, and they can be presented to verifiers to prove claims about the holder of the credential itself. One way to preserve privacy during presentation consists in selectively disclosing the attributes in a credential. In this paper we present the most widespread cryptographic mechanisms used to enable selective disclosure of attributes, describing their structure and comparing them in terms of performance, size of the associated verifiable presentations, and the ability to produce predicate proofs and unlinkable presentations.
引用
收藏
页码:123 / 134
页数:12
相关论文
共 29 条
  • [21] Discovery and first structural disclosure of AZD5305: A next generation, highly selective PARP1 inhibitor and trapper.
    Leo, Elisabetta
    Johannes, Jeffrey
    CANCER RESEARCH, 2021, 81 (13)
  • [22] Discovery and First Structural Disclosure of EZM0414: A potent and selective small molecule inhibitor of the histone methyltransferase SETD2
    Kutok, Jeffery L.
    CANCER RESEARCH, 2022, 82 (12)
  • [23] Identification of a novel series of MTAP-selective PRMT5 inhibitors, and first disclosure of AZ-PRMT5i-1
    Smith, James M.
    Barlaam, Bernard
    Beattie, David
    Cumming, Iain
    Robb, Graeme
    Wilson, David
    Gianni, Davide
    Srinivasan, Bharath
    Stubbs, Chris
    Debreczeni, Judit
    Vazquez-Chantada, Mercedes
    Chiarparin, Elisabetta
    Lynch, James
    Dean, Emma
    CANCER RESEARCH, 2023, 83 (07)
  • [24] Electromagnetic Backscattering Mechanisms of Frequency Selective Surfaces for Effective Analysis of Radar Cross Section by the First-Order Approximation of Floquet Modes
    Chou, Hsi-Tseng
    Lin, Kun-Ying
    Wu, Rui-Zhe
    IEEE TRANSACTIONS ON ELECTROMAGNETIC COMPATIBILITY, 2022, 64 (01) : 75 - 84
  • [25] First Selective Dual Inhibitors of Tau Phosphorylation and Beta-Amyloid Aggregation, Two Major Pathogenic Mechanisms in Alzheimer's Disease
    Mariano, Marica
    Schmitt, Christian
    Miralinaghi, Parisa
    Catto, Marco
    Hartmann, Rolf W.
    Carotti, Angelo
    Engel, Matthias
    ACS CHEMICAL NEUROSCIENCE, 2014, 5 (12): : 1198 - 1202
  • [26] First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson's Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate
    Sun, Huikai
    Monenschein, Holger
    Schiffer, Hans H.
    Reichard, Holly A.
    Kikuchi, Shota
    Hopkins, Maria
    Macklin, Todd K.
    Hitchcock, Stephen
    Adams, Mark
    Green, Jason
    Brown, Jason
    Murphy, Sean T.
    Kaushal, Nidhi
    Collia, Deanna R.
    Moore, Steve
    Ray, William J.
    English, Nicole Marion
    Carlton, Mark Beresford Lewis
    Brice, Nicola L.
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (14) : 9875 - 9890
  • [27] First disclosure of AZD8421, a highly selective CDK2 inhibitor to address resistance to CDK4/6 inhibitors in breast and CCNE1-high cancers
    Denz, Christopher R.
    Grondine, Michael
    Fan, Jun
    Hsu, Jessie Hao-Ru
    Jackson, Anne
    Robinson, James
    Guo, Grace
    Li, Wen
    Wang, Yanjun
    Martin, Maryann San
    Prickett, Laura
    Johannes, Jeffrey
    Ghosh, Avipsa
    Song, Kun
    Sudhan, Dhivya
    Vasalou, Christina
    Richards, Ryan
    Beaumont, Kevin
    Peters, Matthew
    Drew, Lisa
    Fawell, Stephen
    Goldberg, Frederick W.
    CANCER RESEARCH, 2024, 84 (07)
  • [28] First-time disclosure of M3258: A selective inhibitor of the immunoproteasome subunit LMP7 with potential for improved therapeutic utility in multiple myeloma compared to pan-proteasome inhibitors
    Sanderson, Michael
    Busch, Michael
    Esdar, Christina
    Friese-Hamim, Manja
    Krier, Mireille
    Ma, Jianguo
    Musil, Djordje
    Rohdich, Felix
    Sloot, Willem
    Walter, Gina
    Zanelli, Ugo
    Schadt, Oliver
    Klein, Markus
    CANCER RESEARCH, 2019, 79 (13)
  • [29] Discovery of and first disclosure of the clinical candidate AZD9291, a potent and selective third-generation EGFR inhibitor of both activating and T790M resistant mutations that spares the wild type form of the receptor.
    Finlay, M. Raymond V.
    Anderton, Mark
    Ashton, Susan
    Ballard, Peter G.
    Bradbury, Rob H.
    Butterworth, Sam
    Chuaqui, Claudio E.
    Colclough, Nicola
    Cross, Darren A. E.
    McFarland, Heather L.
    Mellor, Martine J.
    Ward, Richard A.
    Waring, Mike J.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)